<DOC>
	<DOCNO>NCT00553475</DOCNO>
	<brief_summary>To evaluate efficacy safety pregabalin 300 mg/day 600 mg/day ( BID ) patient painful diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Randomized , Double-Blind , Multicenter , Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Visual Analogue Scale ( VAS ) pain high 40 mm . Diagnosis type 1 2 diabetes mellitus least 1 year Malignancy within past 2 year . Neurologic disorder unrelated diabetic neuropathy may confuse assessment neuropathy pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>